Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Psychiatry
•
Child & Adolescent Psychiatry
•
Public & Community Psychiatry
•
General Outpatient Psychiatry
In patients with intellectual disability and persistent aggressive behaviors despite multiple antipsychotic trials, have you found pimavanserin to be a useful adjunctive treatment?
Related Questions
When do you consider using Uzedy, the subcutaneous long-acting injectable version of risperidone?
How long do you continue benzodiazepines in patients who have recovered from catatonia?
How do you decide whether to request a welfare check (police or mobile crisis) when a typically responsive outpatient becomes suddenly unreachable?
How do you transition patients between different long-acting injectable antipsychotics?
How do you approach titration or transitioning to Cobenfy in patients currently on an antipsychotic?
How do you discuss sexual and gender identity-related anxiety with teens when family dynamics are rigid or culturally conservative?
What strategies have you found effective for obtaining insurance approval for xanomeline-tropsium (Cobenfy)?
How have you incorporated long-acting injectables into private practice or other settings that haven’t traditionally offered them?
How would you decide between escalation to clozapine vs xanomeline-tropsium (Cobenfy) for treatment-resistant schizophrenia?
What strategies do you use for patients on medications for ADHD who experience afternoon rebound/withdrawal?
